Stockscreener 앱 받기
26.30
2.18%
0.56
시간 외 거래:
26.31
0.010
+0.04%
전일 마감가:
$25.74
열려 있는:
$25.93
하루 거래량:
1.26M
Relative Volume:
0.72
시가총액:
$4.17B
수익:
$1.27M
순이익/손실:
$-508.02M
주가수익비율:
-9.1297
EPS:
-2.8807
순현금흐름:
$-419.23M
1주 성능:
+2.26%
1개월 성능:
+34.73%
6개월 성능:
+55.16%
1년 성능:
+84.56%
1일 변동 폭
$25.36
$26.76
1주일 범위
$25.05
$26.80
52주 변동 폭
$12.58
$26.80
Denali Therapeutics Inc Stock (DNLI) Company Profile
명칭
Denali Therapeutics Inc
전화
(650) 866-8547
주소
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
26.30 | 4.09B | 1.27M | -508.02M | -419.23M | -2.8807 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2026-02-24 | 개시 | Wolfe Research | Peer Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-04-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | 재개 | Morgan Stanley | Overweight |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2025-01-07 | 개시 | Robert W. Baird | Outperform |
| 2025-01-03 | 개시 | William Blair | Outperform |
| 2024-12-16 | 업그레이드 | Stifel | Hold → Buy |
| 2024-10-10 | 재개 | Raymond James | Mkt Perform |
| 2024-10-07 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | 개시 | Citigroup | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-09-06 | 개시 | B. Riley Securities | Buy |
| 2023-01-30 | 개시 | SVB Securities | Outperform |
| 2022-12-05 | 개시 | Cowen | Outperform |
| 2022-11-02 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-11-02 | 개시 | BofA Securities | Buy |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-12-10 | 재개 | Raymond James | Mkt Perform |
| 2021-09-21 | 개시 | Oppenheimer | Outperform |
| 2021-09-01 | 개시 | SMBC Nikko | Outperform |
| 2021-05-18 | 개시 | UBS | Buy |
| 2021-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2021-02-10 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-16 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-08-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-13 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2020-02-28 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2020-02-24 | 개시 | Jefferies | Buy |
| 2020-02-19 | 개시 | Stifel | Hold |
| 2020-01-27 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-09-26 | 개시 | Wedbush | Neutral |
| 2019-09-13 | 개시 | Nomura | Buy |
| 2019-08-09 | 개시 | BTIG Research | Buy |
| 2019-06-26 | 개시 | H.C. Wainwright | Buy |
| 2018-11-15 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-11-12 | 개시 | Janney | Buy |
| 2018-03-12 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2018-01-02 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 개시 | Goldman | Neutral |
| 2018-01-02 | 개시 | JP Morgan | Overweight |
| 2018-01-02 | 개시 | Morgan Stanley | Overweight |
모두보기
Denali Therapeutics Inc 주식(DNLI)의 최신 뉴스
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Trading Systems Reacting to (DNLI) Volatility - Stock Traders Daily
DNLIDenali Therapeutics Inc Volatility & Greeks - Finviz
Denali Therapeutics (DNLI) Looks Fully Valued Following Its 32% 30 Day Rally - Sahm
Denali Therapeutics stock stays focused on pipeline progress. - AD HOC NEWS
Amyotrophic Lateral Sclerosis Market Gains Momentum with Expanding Pipeline and Investment Potential by 2034 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK - Barchart.com
Denali to sell priority review voucher for $195M cash boost - MSN
Enterprise value to EBIT forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to sales forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc (DNLI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh - TradingView
Price to earnings forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Price to book forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
Denali Therapeutics Inc. Actuals & Estimates (NASDAQ:DNLI) - TradingView
Enterprise value to EBITDA forward of Denali Therapeutics Inc. – NASDAQ:DNLI - TradingView
4DN Forecast — Price Target — Prediction for 2027 - TradingView
Denali Therapeutics Inc. Actuals & Estimates (DUS:4DN) - TradingView
How Denali Therapeutics Inc. (DNLI) Affects Rotational Strategy Timing - Stock Traders Daily
Denali Therapeutics options trading jumps to 2,291 contracts By Investing.com - Investing.com India
Denali Therapeutics options trading jumps to 2,291 contracts - Investing.com
Denali Therapeutics stock hits 52-week high at 25.74 USD By Investing.com - Investing.com Nigeria
Denali Therapeutics stock hits 52-week high at 25.74 USD - Investing.com
DNLI Forecast — Price Target — Prediction for 2027 - TradingView
We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate - Moomoo
Denali Therapeutics (DNLI) Q1 2026 earnings summary - Quartr
Denali Therapeutics Sells Rare Pediatric Disease Priority Review Voucher for $195 Million - Global Legal Chronicle
Regenxbio Shares Rise on Plans to Resubmit Navsunli BLA for MPS II - Yahoo Finance
Denali Therapeutics (DNLI) Looks Fully Valued After $195 Million Voucher Sale - Sahm
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million - simplywall.st
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Denali stock, cites launch progress By Investing.com - Investing.com India
Stifel reiterates Buy rating on Denali Therapeutics stock at $41 - Investing.com
Stifel reiterates Buy rating on Denali stock, cites launch progress - Investing.com
Denali to sell priority review voucher for $195M - MSN
Denali Therapeutics StockAnalyst focus and sector check after a quiet news week - AD HOC NEWS
Denali to Sell Priority Review Voucher for $195M Cash Boost - TradingView
Denali Monetizes Rare Pediatric Disease Voucher In $195m Deal After Avlayah FDA Nod - insights.citeline.com
Sector Update: Healthcare Stocks Advance Premarket Thursday - Moomoo
Denali Therapeutics Files 8-K Report Detailing Company Information and Latest Press Release – June 2026 - Minichart
Denali Therapeutics to sell priority review voucher for $195m - Investing.com
Denali Therapeutics to sell priority review voucher for $195m By Investing.com - Investing.com South Africa
Denali Therapeutics Inc (DNLI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Denali Therapeutics Inc (DNLI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Denali to sell priority review voucher for $195M (DNLI:NASDAQ) - Seeking Alpha
Denali Therapeutics Inc (DNLI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
2.48%
자본화:
|
볼륨(24시간):